16 completed, 8 recruiting, 5 terminated, 4 active not recruiting. 46 Phase 1, 18 Phase 2.
Follow Disease Progression: new trials by email Literature Review of Disease Progression trials Research Report on Disease Progression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BLinatumomab and iNKT in Relapsed B-Cell ALL Invariant Natural Killer T Cell Therapy - B-Cell ALL, ALL (Acute B-Lymphoblastic Leukemia) | Phase 1 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 13 | 2026-12-01 | 2026-11-05 |
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-11-17 | 2026-11-12 |
| Surgery After Verifying Existing Disease in Locally Advanced Operable Lung Cancer: A Pilot Study Observation without surgery, Standard-of-care surgery - Non-Small Cell Lung Cancer, Immunotherapy | Phase 1 | Not yet recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 14 | 2026-10-01 | 2026-08-14 |
| Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer Pulse radiotherapy - Non Small Cell Lung Cancer, Metastatic Lung Cancer | Phase 1 | Recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 32 | 2026-08-20 | 2026-08-24 |
| First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma FT536, Biopsy/ Intratumoral Injection/ Gross Tumor Resection, Blood/ Cerebrospinal Fluid/ Tumor Pathology - Astrocytoma, Glioblastoma | Phase 1 | Recruiting | Masonic Cancer Center, University of Minnesota | 9 | 2026-04-23 | 2026-05-01 |
| Vebectotamab Vedotin Combined With Pucotelimab in the Treatment of Locally Advanced Laryngeal Carcinoma Vibecotamab Injection - Head & Neck Cancer | Phase 1 / Phase 2 | Not yet recruiting | Tang-Du Hospital | 10 | 2026-04-23 | 2026-04-20 |
| A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer E-EDV-D682, EDV-GC, Gemcitabine - Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Engeneic Pty Limited | 144 | 2026-01-12 | 2026-02-27 |
| Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy Avasopasem - Breast Cancer Metastatic | Phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | 35 | 2025-10-02 | 2026-11-04 |
| Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM BCMA CART - Ultra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions, Cytogenetics Ultra High Risk | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 50 | 2025-03-03 | 2025-08-07 |
| Relugolix + Enzalutamide Study in High-Risk Prostate Cancer Relugolix and Enzalutamide - Androgen Deprivation Therapy, Locally Advanced Prostate Cancer | Phase 1 | Recruiting | University of Oklahoma | 46 | 2024-12-26 | 2026-03-05 |
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL BMF-219 - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Biomea Fusion Inc. | 55 | 2022-01-24 | 2025-07-03 |
| Enhancing Gait Using Alternating-Frequency DBS in Parkinson Disease High-Frequency-Only Stimulation, Low-Frequency-Only Stimulation, Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation - Parkinson Disease, Gait Disorders, Neurologic | Phase 1 | Active not recruiting | James Liao | 12 | 2021-10-04 | 2026-07-01 |
| CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome CPI-613, Hydroxychloroquine - Myelodysplastic Syndromes, Progressive Disease | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2021-05-01 | 2021-04-14 | |
| A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies RSC-1255 Dose Escalation, RSC-1255 Dose Expansion - Advanced Malignant Solid Neoplasm, RAS Mutation | Phase 1 | Recruiting | RasCal Therapeutics, Inc. | 134 | 2021-03-03 | 2026-06-23 |
| A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies AMXI-5001:Dose Escalation Phase I, AMXI-5001:Dose Expansion Phase II - Advanced Malignant Neoplasm, Breast Cancer | Phase 1 / Phase 2 | Recruiting | AtlasMedx, Incorporated | 122 | 2020-08-12 | 2025-05-01 |
| LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients Lopinavir / Ritonavir, Remdesivir (RDV), Tocilizumab - COVID-19, Hospitalized COVID-19 Patients | Phase 1 | Unknown | Lebanese University | 1000 | 2020-03-28 | 2024-02-06 |
| Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer Binimetinib, Brigatinib - ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma | Phase 1 | Terminated | University of California, San Francisco | 3 | 2020-02-25 | 2022-10-17 |
| Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors KN044 - Advanced Solid Tumors | Phase 1 | Unknown | Changchun Intellicrown Pharmaceutical Co. LTD | 39 | 2020-01-09 | 2023-09-01 |
| Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia Gemtuzumab Ozogamicin (GO), Donor Leukocytes - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Brown University | 11 | 2019-12-31 | 2026-07-23 |
| Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies Pembrolizumab, Autologous dendritic cells, Interleukin-2 - Mesothelioma, Malignant, PD-L1 Negative | Phase 1 | Active not recruiting | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 18 | 2019-12-12 | 2024-10-01 |
Showing 20 of 46. Sign in to see all of them.
Pathologic Complete Response (10) · Neoplasms (9) · Leukemia, Myeloid, Acute (7) · Recurrence (5) · Carcinoma, Non-Small-Cell Lung (4) · Leukemia (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lung Neoplasms (4) · Multiple Myeloma (4) · Pancreatic Neoplasms (4) · Brain Neoplasms (3) · Colonic Neoplasms (3) · Glioblastoma (3) · Lymphoma, Non-Hodgkin (3)
Disease Attributes (46) · Pathologic Processes (46) · Pathological Conditions, Signs and Symptoms (46) · Neoplasms (29) · Neoplasms by Histologic Type (24) · Neoplasms by Site (19) · Hemic and Lymphatic Diseases (15) · Hematologic Diseases (14) · Immune System Diseases (10) · Lung Diseases (10) · Respiratory Tract Diseases (10) · Immunoproliferative Disorders (9) · Lymphoproliferative Disorders (9) · Respiratory Tract Neoplasms (8)
Blood Specimen Collection (2) · Gemcitabine (2) · Melphalan (2) · durvalumab (2) · fludarabine (2) · AZD 6244 (1) · Antilymphocyte Serum (1) · Azacitidine (1) · Biopsy (1) · Bone Marrow Transplantation (1) · Busulfan (1) · Carboplatin (1) · Cetuximab (1) · Cisplatin (1) · Clinical Trials, Phase I as Topic (1)
M.D. Anderson Cancer Center (5) · National Cancer Institute (NCI) (3) · AstraZeneca (2) · Centre hospitalier de l'Université de Montréal (CHUM) (2) · Engeneic Pty Limited (2) · University of Pennsylvania (2) · AtlasMedx, Incorporated (1) · Biomea Fusion Inc. (1) · Brown University (1) · Celgene (1) · Changchun Intellicrown Pharmaceutical Co. LTD (1) · Coronado Biosciences, Inc. (1) · GlaxoSmithKline (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS (1)
United States (34) · China (3) · Italy (3) · Canada (2) · United Kingdom (2) · France (1) · Germany (1) · Greece (1) · Ireland (1) · Lebanon (1) · Netherlands (1) · Spain (1) · Sweden (1)
Pamela Munster, MD (2) · Teri N Kreisl, M.D. (2) · Agop Y. Bedikian, MD, BS (1) · Andrew Haas, MD, PhD (1) · Andrew Poklepovic, MD (1) · Antoine Desilets, MD, MSc (1) · Bayard Powell, MD (1) · Collin Blakely, MD, PhD (1) · Damiano Rondelli, MD (1) · David S Schrump, M.D. (1) · Dehui Zou (1) · Dr Himanshu Brahmbhatt, Ph.D (1) · Dr Jennifer MacDiarmid, Ph.D (1) · Dr Linda Y.Wu, MD (1) · Edward Stadtmauer, MD (1)
PMID 24777247, PMID 25778529, PMID 26352815, PMID 29065747, PMID 29658848, PMID 29669947, PMID 32379297, PMID 32476546, PMID 34482636, PMID 37560967, PMID 37587502, PMID 37783947, PMID 39509670, PMID 41528970, PMID 42031503
2016 (1), 2025 (1), P01CA148600 (1), P30CA012197 (1), P30CA016672 (1)